US EditionWhy more teens are getting kidney stones, and what can be done to prevent them
- Kidney transplant recipients with type 2 diabetes who took GLP-1 agonists had a 49% lower chance of organ failure compared to those who did not take the drugs.
- Those patients had a 31% reduced risk of dying within five years of beginning the medication.
- The study revealed an increased risk of diabetic retinopathy among GLP-1 users, highlighting the need for eye health monitoring.
- The research provided strong evidence for the safety and effectiveness of GLP-1 medications for these patients.
51 Articles
51 Articles
Why more teens are getting kidney stones, and what can be done to prevent them
Anyone who has ever had a kidney stone will probably never forget it. More health stories Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds What your peeing frequency can say about your health A Patient’s Guide to Kidney Disease “They can be incredibly painful,” said pediatrician Christine Ashburn, with Kaiser Permanente. Kidney sto…
Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes
Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.
Use of GLP-1 Drugs for Obesity Linked to Lower Risk of Glaucoma
(MedPage Today) -- Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ocular hypertension compared with other weight-loss medications, a retrospective cohort study suggested...
Coverage Details
Bias Distribution
- 61% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
